A detailed history of Abound Wealth Management transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Abound Wealth Management holds 1 shares of BGNE stock, worth $206. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$206
Previous $143,000 57.34%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 08, 2024

BUY
$178.3 - $266.78 $178 - $266
1 New
1 $179,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $21.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Abound Wealth Management Portfolio

Follow Abound Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abound Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Abound Wealth Management with notifications on news.